NVO stock: buy or sell?

NVO stock price: $63.40 -2.21% At close on May 26th, 2020

Updated on:
May 26th, 2020


After reaching all time highs on Wednesday, Novo Nordisk A/S eased -2.21% to $63.40.

Novo Nordisk A\u002FS, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide.

Should I buy NVO stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

None of our preferred buy setups matches with Novo Nordisk A/S stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Novo Nordisk A/S stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. Unfortunately, we couldn't detect any rating for NVO stock for the last 30 days.

NVO stock analysis

Daily outlook

After several days of continuous hikes in past weeks, Novo Nordisk A/S eased -2.21% to $63.40.

After several days of continuous rises in past weeks, Novo Nordisk A/S eased -2.21% to $63.40. Since price and SMA200d lines crossed up on March, NVO climbed $11.11 (21.25%). In the last 4 days when SMA50d and SMA100d crossed up, NVO price slipped $-1.42 per share (-2.19%). On Wednesday, NVO hit a new all time high, pushing higher than on Apr/28 tops. Check different trading setups that use ATHs as triggers.

NVO stock chart (daily)

Weekly outlook

Novo Nordisk A/S declined a tragic -2.21% this week.

Not so far away is the last all-time high Novo Nordisk A/S marked last week. Since late March when NVO stock price broke up the SMA40w line, it gained $14.62 (29.97%). Since SMA10w and SMA20w crossed up last week, NVO price slid a -0.80%.

NVO stock chart (weekly)

NVO stock price history

NVO stock went public on April 28th, 1992 with a price of $0.011. Since then, NVO stock grew a 633,900.00%, with an average of 22,639.30% per year. If you had invested right after NVO's IPO a $1,000 in NVO stock in 1992, it would worth $6,339,000.00 today.

1: Adjusted price after possible price splits or reverse-splits.

NVO stock historical price chart

NVO stock reached all-time highs on Wednesday with a price of $66.02.

NVO stock price target

How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we have not detected any price target for Novo Nordisk A/S stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

, Novo Nordisk A/S missed the estimates of the experts and posted a bad EPS of $0.54 per share when experts were expecting $0.57.
NVO earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual revenues report draw a neutral movement of 0.12% to $111,831.00 M dollars. Similarly, its income margin (compared to sales) stayed steady to 34.54%, that is $38,628.00 million.

NVO annual Sales and Income evolution
2013$83,570 M-$25,180 M30.1%-
2014$14,427 M-82.74%$4,302 M29.8%-82.92%
2015$107,927 M648.09%$34,860 M32.3%710.33%
2016$111,780 M3.57%$37,925 M33.9%8.79%
2017$111,696 M-0.08%$38,130 M34.1%0.54%
2018$111,831 M0.12%$38,628 M34.5%1.31%

Quarterly financial results

Novo Nordisk A/S posted $29,732.00 M in sales for 2018-Q4, a 7.10% up compared to previous quarter. Reported quarter income marked $8,497.00 M with a profit margin of 28.58%. Profit margin slightly fell a -3.97% compared to previous quarter when profit margin was 32.55%. When comparing sales to same quarter last year, Novo Nordisk A/S sales marked an outstanding increase and rocketed a 559.07%. Looking back to recent quarterly results, Novo Nordisk A/S posted 5 negative quarters in a row.
NVO quarterly Sales and Income evolution
2017-Q1$28,450 M-$10,160 M35.7%-
2017-Q2$28,640 M0.67%$9,950 M34.7%-2.07%
2017-Q3$4,200 M-85.34%$1,542 M36.7%-84.51%
2017-Q4$4,511 M7.42%$1,330 M29.5%-13.73%
2018-Q1$26,930 M496.96%$10,751 M39.9%708.32%
2018-Q2$27,407 M1.77%$10,343 M37.7%-3.79%
2018-Q3$27,762 M1.30%$9,037 M32.6%-12.63%
2018-Q4$29,732 M7.10%$8,497 M28.6%-5.98%

Novo Nordisk A/S ownership

Having a look at Novo Nordisk A/S ownership structure gives valuable information about the company and its governance (insider ownership) or the amount of investors that are on the short side.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Novo Nordisk A/S, 0.01% of all outstanding shares are owned by its staff.

In case of Novo Nordisk A/S stock, 9.48% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NVO stock account 0.00%, no big difference from last month.

For a better context understanding, the following table shows ownership data compared to other related companies:

Market cap$148.4 B
Total shares2,340.0 M
Float shares1,670.0 M
  - Institutional holdings (%)9.5%
  - Insider holdings (%)0.0%
Shares in short selling0.0%

NVO summary

Tuesday, May 26th, 2020
Day range$63.34 - $64.61
Previous close$64.83
Session gain-2.21%
Average true range$1.23
50d mov avg$60.46
100d mov avg$60.23
200d mov avg$56.74
Daily pattern
Weekly pattern

Novo Nordisk A/S performance

To better understand Novo Nordisk A/S performance you must becnhmark its gains with other related stocks in same sector or industry. We compared Novo Nordisk A/S against in the following table:

Novo Nordisk A/S competitors

Unfortunately, we could not find any public company that could be defined as Novo Nordisk A/S competitor. This doesn't mean Novo Nordisk A/S does not have any competitor in the market, it's just we could not detected it.

    Latest NVO stock news